文献速递肝胆胰外科围术期管理与 ERAS

腹腔镜肝再切除治疗肝癌术后复发可行性的倾向性评分匹配研究

Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study.
PubMed 文献 · Surg Endosc · 2017-04-07

本研究纳入2008年至2015年间30例肝癌切除术后复发接受腹腔镜肝再切除的患者,经1:1倾向性评分匹配与开腹再切除比较。结果显示腹腔镜组出血量、输血率、并发症率和住院时间更优,无病生存与总生存与开腹组相当。

要点

  • 腹腔镜肝再切除可安全用于肝癌术后复发,围术期结局优于开腹
  • 腹腔镜组输血率和并发症率显著低于开腹组
  • 两组无病生存和总生存无显著差异

核心结论

  • 腹腔镜肝再切除治疗肝癌术后复发提供与开腹再切除相当的围术期和肿瘤学结局,可作为安全替代。

研究设计与样本

  • 采用1:1倾向性评分匹配比较腹腔镜与开腹肝再切除的短期和长期结局。

主要发现

  • 腹腔镜组与开腹组手术时间分别为200.5分钟与207.50分钟(p=0.903)。
  • 腹腔镜组与开腹组出血量分别为100 ml与400 ml(p=0.000196)。
  • 腹腔镜组与开腹组输血率分别为0.0%与43.3%(p=0.000046),并发症率分别为6.7%与30.0%(p=0.01)。
  • 腹腔镜组与开腹组住院时间分别为9.5天与13.5天(p=0.000008)。
  • 中位随访35个月,1年、3年、5年无病生存率腹腔镜组为79.0%、51.0%、31.9%,开腹组为78.3%、57.4%、43.0%(p=0.474);总生存率腹腔镜组为89.4%、75%、67.5%,开腹组为96.7%、85.0%、74.4%(p=0.413)。

临床怎么用

  • 对于肝癌切除术后复发患者,腹腔镜肝再切除可作为开腹手术的安全替代,有助于减少出血、输血、并发症和缩短住院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver re-resection plays a paramount role in treatment of patients with posthepatectomy hepatocellular carcinoma (HCC) recurrence. Laparoscopic liver resection has been a feasible alternative to open surgery. However, whether laparoscopic liver re-resection for posthepatectomy HCC recurrence is better than open liver re-resection remains unknown. METHOD: From January 2008 to December 2015, 30 patients with recurrent HCC after prior liver resection underwent laparoscopic liver re-resection in our center. To minimize any confounding factors, a propensity score matching study using a patient ratio of 1:1 was conducted to compare the short- and long-term outcomes of patients who underwent laparoscopic or open liver re-resection. RESULT: With the open surgery group compared laparoscopic group, operative time was 207.50 versus 200.5 min (p = 0.903), blood loss was 400 versus 100 ml (p = 0.000196), blood transfusion rate was 43.3 versus 0.0% (p = 0.000046), complication rates were 30.0 versus 6.7% (p = 0.01), and hospital stay was 13.5 versus 9.5 days (p = 0.000008). The median follow-up was 35 months. The 1-year, 3-year, 5-year disease-free survival rates were 79.0, 51.0, and 31.9%, versus 78.3, 57.4, and 43.0%, respectively (p = 0.474). The 1-year, 3-year, and 5-year overall survival rates were 89.4, 75, and 67.5%, versus 96.7, 85.0, and 74.4%, respectively (p = 0.413). CONCLUSION: Laparoscopic liver re-resection for patients with posthepatectomy HCC recurrence provided comparable perioperative and oncological outcomes as open liver re-resection and can be a safe alternative to open procedure.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Liu K, Chen Y, Wu X, et al. Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study. Surg Endosc. 2017. PMID: 28389803. doi:10.1007/s00464-017-5556-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。